0000000000347621
AUTHOR
José Ferrer-rebolleda
Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial
Background: Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet efective substances are recommended. There is a need to develop new drugs to delay Alzheimer’s dementia. We have taken a nutritional supplement approach with genistein, a chemically defned polyphenol that acts by multimodal specifc mechanisms. Our group previously showed that genistein supplementation is efective to treat the double transgenic (APP/PS1) AD animal model. Methods: In this…
Additional file 1 of Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial
Additional file 1: Table S1. All possible comparisons of the values for the anterior cingulate gyrus before and after treatment with placebo or genistein.